Obstetric antiphospholipid antibody syndrome (APS), is well defined by classification criteria. It is well known that women with APS should receive prophylactic anticoagulation therapy with subcutaneous low weight heparin all throughout pregnancy and in the first 6 weeks postpartum. However, the optimal treatment for pregnant women having positive anti-phospholipid antibodies, but not fullfilling classification criteria for APS is still unclear. In this retrospective study we report pregnancy outcomes of 10 patients affected by recurrent miscarriages and positive anti-cardiolipin or aβ2GP1 antibodies with titers ranging from 10 to 20 GPL/MPL demonstrated at least twice before pregnancy.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis2006; 4:295–306.
2.
ClarkCADavidovitsJSpitzerKALaskinCA. The lupus anticoagulant: Results from 2257 patients attending a high-risk pregnancy clinic. Blood2013; 122(3):341–7.
3.
BenedettoCMarozioLTavellaAM. Coagulation disorders in pregnancy: Acquired and inherited thrombophilias. Ann. NY Acad. Sci2010; 1205:106–17.
4.
Kwak-KimJAgcaoiliMSAletaL. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol2013; 69:596–607.
5.
GleicherNElkayamU. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials. Autoimmun Rev2013; 12(11):1039–45.
6.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum1997; 40:1725.
7.
BurtTD. Fetal regulatory T cells and peripheral immune tolerance in utero: Implications for development and disease. Am J Reprod Immunol2013;69(4):346–58.
8.
BradleyLAPalomakiGEBienstockJVargaEScottJA. Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes? Results from a targeted evidence-based review. Genet Med2012; 14:39–50.
9.
PabimgerI. Thrombophilia and its impact on pregnancy. Thromb Res2009; 123:516–21.
10.
KovacMMiticGMikovicZ. Thrombophilia in women with pregnancy-associated complications: Fetal loss and pregnancy-related venous thromboembolism. Gynecol Obstet Invest2012; 69:233–38.
11.
Van MensTELeviMMiddeldorpS. Evolution of Factor V Leiden. Thromb Haemost2013; 110: 23–30.
12.
KovacMMikovicZMiticGDjordjevicVMandicVRakicevicLRadojkovicD. Does anticoagulant therapy improve pregnancy outcome equally, regardless of specific thrombophilia type?Clin Appl Thromb/Haemostatsis2014; 20(2): 184–9.
13.
DeSanchoMTBerlusNChristosPJRandJ. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. Blood Coagul Fibrinolysis2010; 21:11–5
14.
Vega-OstertagMEPierangeliSS. Mechanisms of aPL-mediated thrombosis: Effects of aPL on endothelium and platelets. Curr Rheumatol Rep2007;9:190–7.
15.
AfeltraAVadaccaMContiL. Thrombosis in systemic Lupus Erythematosus: Congenital and acquired risk factors. Arthritis Rheum2005; 3:452–59.
